Publications by authors named "Noopur Shankar"
Article Synopsis
- * In a phase 3 trial involving 325 patients, those taking inavolisib had a median progression-free survival of 15.0 months, significantly better than the 7.3 months for the placebo group, indicating better disease management.
- * The treatment with inavolisib showed promising results with a 58.4% objective response rate; however, there were notable side effects, similar between both groups, including high rates of neutropenia
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Komal L Jhaveri Melissa K Accordino Philippe L Bedard Andrés Cervantes Valentina Gambardella Noopur Shankar
J Clin Oncol
November 2024
Article Synopsis
- The study aimed to assess the safety, tolerability, and effectiveness of inavolisib combined with palbociclib and endocrine therapy for patients with specific types of breast cancer.
- A total of 53 patients participated, experiencing some treatment-related side effects, with common issues being stomatitis, hyperglycemia, and diarrhea, but overall the treatment was manageable.
- Results showed promising preliminary antitumor activity, with objective response rates of about 52% and 40%, and median progression-free survival of 23.3 and 35.0 months for different treatment combinations.
Exposure-response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dose intensities were summarized by tertiles of predicted venetoclax steady-state average concentrations based on nominal venetoclax dose () for tolerability; exposure-safety analyses used logistic regression. Exposure-progression-free survival (PFS) relationships were assessed using MURANO data, with as a grouping factor.
View Article and Find Full Text PDF